In perspective: An update on telomere targeting in cancer

Eric T. Sugarman, Gao Zhang, Jerry W. Shay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Engaging a telomere maintenance mechanism during DNA replication is essential for almost all advanced cancers. The conversion from normal and premalignant somatic cells to advanced malignant cells often results (85%-90%) from the reactivation of the functional ribonucleoprotein holoenzyme complex, referred to as telomerase. Modulation of the human telomerase reverse transcriptase (hTERT) appears to be rate limiting to produce functional telomerase and engage a telomere maintenance mechanism. The remaining 10% to 15% of cancers overcome progressively shortened telomeres by activating an alternative lengthening of telomeres (ALT) maintenance mechanism, through a DNA recombination pathway. Exploration into the specific mechanisms of telomere maintenance in cancer have led to the development of drugs such as Imetelstat (GRN163L), BIBR1532, 6-thio-dG, VE-822, and NVP-BEZ235 being investigated as therapeutic approaches for treating telomerase and ALT tumors. The successful use of 6-thio-dG (a nucleoside preferentially recognized by telomerase) that targets and uncaps telomeres in telomerase positive but not normal telomerase silent cells has recently shown impressive effects on multiple types of cancer. For example, 6-thio-dG overcomes therapy-resistant cancers in a fast-acting mechanism potentially providing an alternative or additional route of treatment for patients with cancer. In this perspective, we provide a synopsis of the current landscape of telomeres and telomerase processing in cancer development and how this new knowledge may improve outcomes for patients with cancer.

Original languageEnglish (US)
Pages (from-to)1581-1588
Number of pages8
JournalMolecular Carcinogenesis
Volume58
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Telomere
Telomerase
Neoplasms
Telomere Homeostasis
Maintenance
Telomere Shortening
Holoenzymes
Ribonucleoproteins
DNA Replication
Nucleosides
Genetic Recombination
Therapeutics
DNA

Keywords

  • 6-thio-dG
  • ALT
  • BRAF
  • hTERC
  • hTERT
  • melanoma
  • telomerase

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

In perspective : An update on telomere targeting in cancer. / Sugarman, Eric T.; Zhang, Gao; Shay, Jerry W.

In: Molecular Carcinogenesis, Vol. 58, No. 9, 01.01.2019, p. 1581-1588.

Research output: Contribution to journalArticle

Sugarman, Eric T. ; Zhang, Gao ; Shay, Jerry W. / In perspective : An update on telomere targeting in cancer. In: Molecular Carcinogenesis. 2019 ; Vol. 58, No. 9. pp. 1581-1588.
@article{edaeaedb3aa44bee92dfc3aafb094930,
title = "In perspective: An update on telomere targeting in cancer",
abstract = "Engaging a telomere maintenance mechanism during DNA replication is essential for almost all advanced cancers. The conversion from normal and premalignant somatic cells to advanced malignant cells often results (85{\%}-90{\%}) from the reactivation of the functional ribonucleoprotein holoenzyme complex, referred to as telomerase. Modulation of the human telomerase reverse transcriptase (hTERT) appears to be rate limiting to produce functional telomerase and engage a telomere maintenance mechanism. The remaining 10{\%} to 15{\%} of cancers overcome progressively shortened telomeres by activating an alternative lengthening of telomeres (ALT) maintenance mechanism, through a DNA recombination pathway. Exploration into the specific mechanisms of telomere maintenance in cancer have led to the development of drugs such as Imetelstat (GRN163L), BIBR1532, 6-thio-dG, VE-822, and NVP-BEZ235 being investigated as therapeutic approaches for treating telomerase and ALT tumors. The successful use of 6-thio-dG (a nucleoside preferentially recognized by telomerase) that targets and uncaps telomeres in telomerase positive but not normal telomerase silent cells has recently shown impressive effects on multiple types of cancer. For example, 6-thio-dG overcomes therapy-resistant cancers in a fast-acting mechanism potentially providing an alternative or additional route of treatment for patients with cancer. In this perspective, we provide a synopsis of the current landscape of telomeres and telomerase processing in cancer development and how this new knowledge may improve outcomes for patients with cancer.",
keywords = "6-thio-dG, ALT, BRAF, hTERC, hTERT, melanoma, telomerase",
author = "Sugarman, {Eric T.} and Gao Zhang and Shay, {Jerry W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mc.23035",
language = "English (US)",
volume = "58",
pages = "1581--1588",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - In perspective

T2 - An update on telomere targeting in cancer

AU - Sugarman, Eric T.

AU - Zhang, Gao

AU - Shay, Jerry W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Engaging a telomere maintenance mechanism during DNA replication is essential for almost all advanced cancers. The conversion from normal and premalignant somatic cells to advanced malignant cells often results (85%-90%) from the reactivation of the functional ribonucleoprotein holoenzyme complex, referred to as telomerase. Modulation of the human telomerase reverse transcriptase (hTERT) appears to be rate limiting to produce functional telomerase and engage a telomere maintenance mechanism. The remaining 10% to 15% of cancers overcome progressively shortened telomeres by activating an alternative lengthening of telomeres (ALT) maintenance mechanism, through a DNA recombination pathway. Exploration into the specific mechanisms of telomere maintenance in cancer have led to the development of drugs such as Imetelstat (GRN163L), BIBR1532, 6-thio-dG, VE-822, and NVP-BEZ235 being investigated as therapeutic approaches for treating telomerase and ALT tumors. The successful use of 6-thio-dG (a nucleoside preferentially recognized by telomerase) that targets and uncaps telomeres in telomerase positive but not normal telomerase silent cells has recently shown impressive effects on multiple types of cancer. For example, 6-thio-dG overcomes therapy-resistant cancers in a fast-acting mechanism potentially providing an alternative or additional route of treatment for patients with cancer. In this perspective, we provide a synopsis of the current landscape of telomeres and telomerase processing in cancer development and how this new knowledge may improve outcomes for patients with cancer.

AB - Engaging a telomere maintenance mechanism during DNA replication is essential for almost all advanced cancers. The conversion from normal and premalignant somatic cells to advanced malignant cells often results (85%-90%) from the reactivation of the functional ribonucleoprotein holoenzyme complex, referred to as telomerase. Modulation of the human telomerase reverse transcriptase (hTERT) appears to be rate limiting to produce functional telomerase and engage a telomere maintenance mechanism. The remaining 10% to 15% of cancers overcome progressively shortened telomeres by activating an alternative lengthening of telomeres (ALT) maintenance mechanism, through a DNA recombination pathway. Exploration into the specific mechanisms of telomere maintenance in cancer have led to the development of drugs such as Imetelstat (GRN163L), BIBR1532, 6-thio-dG, VE-822, and NVP-BEZ235 being investigated as therapeutic approaches for treating telomerase and ALT tumors. The successful use of 6-thio-dG (a nucleoside preferentially recognized by telomerase) that targets and uncaps telomeres in telomerase positive but not normal telomerase silent cells has recently shown impressive effects on multiple types of cancer. For example, 6-thio-dG overcomes therapy-resistant cancers in a fast-acting mechanism potentially providing an alternative or additional route of treatment for patients with cancer. In this perspective, we provide a synopsis of the current landscape of telomeres and telomerase processing in cancer development and how this new knowledge may improve outcomes for patients with cancer.

KW - 6-thio-dG

KW - ALT

KW - BRAF

KW - hTERC

KW - hTERT

KW - melanoma

KW - telomerase

UR - http://www.scopus.com/inward/record.url?scp=85070885240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070885240&partnerID=8YFLogxK

U2 - 10.1002/mc.23035

DO - 10.1002/mc.23035

M3 - Article

C2 - 31062416

AN - SCOPUS:85070885240

VL - 58

SP - 1581

EP - 1588

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 9

ER -